Targets › RS1
1 program from 1 company in 1 trial: 1 Phase 3; Other; next expected readout Apr 2028.
Binds negatively charged membrane lipids, such as phosphatidylserine and phosphoinositides (By similarity). May play a role in cell-cell adhesion processes in the retina, via homomeric interaction between octamers present on the surface of two neighboring cells. (UniProt, O15537)
Open in Phaseline: the race on RS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Atsena Therapeutics | ATSN-201 AAV gene therapy delivering hRS1 under hGRK1 promoter | RS1 | Phase 3 | X-linked Retinoschisis | Apr 2028 |
X-linked Retinoschisis (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.